NEW YORK, January 23, 2023–(BUSINESS WIRE)–On January 24, 2023, The Journal of Clinical Psychiatry – Primary Care Companion for CNS Disorders, will publish an article developed by Haymarket Medical Education in conjunction with an expert panel chaired by Russell Rosenberg, PhD, FAASM, Scientific Director and CEO from NeuroTrials Research, Inc., on the management of insomnia disorders in the primary care setting.
“A 2023 Update on Managing Insomnia in Primary Care: Insights From an Expert Consensus Group” is the result of the March 2022 meeting of the Insomnia Task Force, a consensus group of experts in insomnia in primary care, psychiatry and in clinical research, which included a patient with insomnia. The panel convened to identify gaps in the recognition, diagnosis and management of insomnia in primary care and to review new data on available and emerging insomnia treatments. The initiative was supported by an independent educational grant from Eisai.
Authors included Russell P. Rosenberg, PhD, FAASM, Chief Scientific Officer and CEO of NeuroTrials Research Inc., Atlanta, GA, Ruth Benca, MD, PhD, Chair of Psychiatry and Behavioral Medicine at Wake Forest School of Medicine, Winston- Salem, NC, Paul Doghramji, MD, FAAFP, family physician at Collegeville Family Practice and Ursinus College, Collegeville, PA, and Thomas Roth, PhD, founder of the Sleep Disorders and Research Center at Henry Ford Hospital, and clinical professor, Department of Psychiatry, University of Michigan College of Medicine, Ann Arbor, MI. They concluded that despite being widespread, having a profound negative effect on daytime functioning and overall health and occurring comorbidly, but usually not secondary to, multiple medical and psychiatric illnesses, insomnia is under-recognized and under-treated in primary care settings.
The January 24 article details evidence that treating insomnia disorders can lead to improvements in comorbid conditions and quality of life. Committee members recommend that primary care clinicians proactively screen for signs of insomnia, especially in patients with medical or psychiatric illnesses.
Dr Rosenberg said: “Data demonstrating a relationship between insomnia disorder and significant medical conditions is growing, suggesting that clinicians need to take insomnia disorder seriously.”
The panel also recommends lifestyle strategies and sleep hygiene techniques, as well as cognitive behavioral therapy for insomnia; however, these interventions may need to be included as part of a broader treatment strategy. Effective treatment combines pharmacological and non-pharmacological strategies aimed at a personalized approach to reduce sleep onset time, maintain adequate sleep duration, and prevent early awakening, while improving daytime function. Recent developments in the treatment of insomnia disorders have led to the development of a new class of drugs, dual orexin receptor antagonists, with a novel mechanism of action that has been shown to be effective and safe. safety in insomnia disorders.
“It is important to understand that insomnia and conditions such as chronic pain and depression have a two-way relationship. So, for example, to optimize treatment and prevent relapses of depression, improved sleep is essential” , said Dr. Roth.
The article is currently under embargo and will be published on Psychiatry.com at 4 a.m. on January 24, 2023.
About Haymarket Media, Inc.
Haymarket Media, Inc. creates award-winning specialty content and services for a global b2b audience. With over 25 leading marketing brands, Haymarket delivers unrivaled expertise and insight through balanced, relevant and original content across healthcare and corporate media. Our brands connect people and communities across digital, mobile, print and live platforms.
Haymarket is home to highly regarded healthcare brands such as: Clinical Advisor, MPR and Haymarket Medical Education, as well as esteemed trade media titles PRWeek and Medical Marketing & Media.
Haymarket Media, Inc. is the US division of Haymarket Media Group headquartered in the UK. For more information, please visit www.haymarket.com.
About Haymarket Medical Education and myCME
Recognized as a global leader in continuing education, HME and its sister website, myCME, reach 2.2 million healthcare professionals across multiple specialties with relevant, engaging and practical training that positively impacts performance clinics and patient outcomes. HME is an Accreditation Council for Continuing Medical Education (ACCME) accredited CME provider. To learn more, visit Haymarketmedicaleducation.com or www.myCME.com.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20230123005775/en/
Jacqui Brooks, MBBCh, MRCPsych, Vice President of Medical Affairs, Haymarket Medical Education at firstname.lastname@example.org